Currently, a standard third-line therapy for Helicobacter pylori (H. pylori) eradication remains to be established. Quinolones show good oral absorption, no major side effects, and marked activity against H. pylori. Several authors have studied quinolone-based third-line therapy and reported encouraging results, with the reported H. pylori cure rates ranging from 60% to 84%. Resistance to quino...

Sir, BMS-284756 (T-3811) is a novel quinolone that lacks a fluorine at the C-6 position, and is active in vitro against Streptococcus pneumoniae, including strains with elevated ciprofloxacin MICs. Because the various quinolones differ in both target affinity and their activation of efflux pumps, one can speculate that the phenotypic expression of quinolone resistance will also differ. Studies ...

Objective: The purpose of this randomized, crossover study was to compare the bioavailability of a generic and innovator formulation of gatifloxacin 400 mg tablets under fasting conditions. Methods: Seventeen blood samples per period were collected from 24 healthy, Arab male volunteers over 36 hours, plasma gatifloxacin concentrations were determined by HPLC assay, and pharmacokinetic parameter...

The objective of this study was to formulate sodium alginate based ophthalmic mucoadhesive system of gatifloxacin and its in vitro antibacterial potential on pathogenic microorganisms, Staphylococcus aureus and Escherichia coli. Sodium carboxymethylcellulose (NaCMC) was added to the formulations to enhance the gel bioadhesion properties. The prepared formulations were evaluated for their in vit...

Sir, A recent review by Smith et al.1 and associated correspondence2,3 raised important unresolved issues regarding which quinolones exert dual activity through gyrase and topoisomerase IV in Streptococcus pneumoniae. Dual action involves the substantial engagement of both enzyme killing pathways and is of particular interest in potentially limiting the emergence of resistance. Smith et al.3 co...